| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Actinium Pharmaceuticals, Inc. (Delaware)$0.93
-0.04 (-4.12%)
C 41Pipeline Score Fair Value Pharma · Clinical
Market Cap
37.02 M
EPS
-0.75
P/E Ratio
-
Value Trade
281.37 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.20 M
Operating CF
-5.87 M
Total Assets
45.44 M
Total Liabilities
43.13 M
Equity
2.30 M
D/E Ratio
12,345
-7.09 %
Week
-22.37 %
1 Month
5.36 %
3 Month
-7.81 %
6 Month
-85.14 %
5 Year
-64.24 %
All Time
Cash Data
Cash Position
42.13 M
Monthly Burn
1.96 M
Runway
19.6 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
75.89 K
52 Week Range
0.95 - 1.95
% held by Insiders
0.6 %
% held by Institutions
16.9 %
Enterprise Value
-3.59 M
Total Shares
31.38 M
Short %
2.97 %
Float Shares
31.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Actinium Pharmaceuticals, Inc. (Delaware)
588Total events
3Upcoming
105Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 3
Event history 585
Q3 2026
◆Timing GuidancePresentation
Multiple catalysts for ATNM-400, Actimab-A and Iomab-ACT expected in 2H 2026
Jun 26, 2026
Jun 2, 2026
◆Oral PresentationATNM-400Presentation
Oral presentation of ATNM-400 data at SNMMI 2026
prostate cancersource ↗
Jun 2, 2026
◆Poster PresentationATNM-400Presentation
ATNM-400 poster on prostate cancer models at SNMMI 2026
prostate cancersource ↗
Jun 1, 2026
May 31, 2026
◆Poster PresentationPresentation
Poster on optimizing chelator-to-antibody ratio for 225Ac-labeled antibodies at SNMMI 2026
May 29, 2026
▲Patent GrantedActimab-AIP / Competition
Canadian patent allowance for Actimab-A + CLAG-M combination in AML
acute myeloid leukemia (AML)source ↗
May 29, 2026
▲Patent GrantedIomab-ACTIP / Competition
Canadian patent allowance for Iomab-ACT conditioning approach
gene-edited cell-based therapiessource ↗
May 29, 2026
▼Restructuring LayoffsCorporate
NYSE American notice of non-compliance with continued listing standards
Apr 22, 2026
▲Poster PresentationATNM-400Presentation
Preclinical data for ATNM-400 presented at AACR 2026
solid tumors (prostate, lung, breast cancer)source ↗
Apr 22, 2026
◆Oral PresentationActimab-APresentation
Actimab-A data presented at AACR 2026 Annual Meeting
acute myeloid leukemia (AML)source ↗
Apr 21, 2026
◆Poster PresentationATNM-400Presentation
ATNM-400 poster presentation at AACR 2026
solid tumorssource ↗
Drug Pipeline Intelligence
C41
Pipeline Score $94M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored2.5x
rNPV / MCap Top 60%
Micro Cap (rank 365 of 911)
Percentile RankActinium Pharmaceuticals, Inc. (Delaware) carries a moderate pipeline score (41/100), with $1.5B risk-adjusted pipeline value, led by 131I-apamistamab in Acute Leukemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131I-apamistamab Small molecule | Acute Leukemia | Phase 3 | NCT07157514 | 42% | $1.0B | NOT YET_RECRUITING | 306 | VERY_FAST | D (23) | Feb 1, 2034 | ELEVATED_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Actimab-A | acute myeloid leukemia (AML) | — | 2026-04-22 | significant AML cell killing; robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53); demonstrated compelling clinical activity and a manageable safety profile in more than 150 AML patients Read More | Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting Read More | |
Actimab-A | acute myeloid leukemia (AML) | — | 2026-04-22 | significant AML cell killing; robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53); demonstrated compelling clinical activity and a manageable safety profile in more than 150 AML patients Read More | Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting Read More | |
Actimab-A | acute myeloid leukemia (AML) | — | 2026-04-22 | significant AML cell killing; robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53); demonstrated compelling clinical activity and a manageable safety profile in more than 150 AML patients Read More | Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATNM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATNM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATNMActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Actinium Pharmaceuticals showcased new findings on ATNM-400 during the SNMMI 2026 Annual Meeting. The data suggests that ATNM-400 may effectively overcome resistance to all three approved androgen receptor inhibitors in prostate cancer. Additionally, the presentation emphasized the drug's flexible and well-tolerated dosing in relevant cancer models.
Read more →ATNMActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Actinium Pharmaceuticals presented new preclinical data on its investigational treatment, ATNM-400, at the SNMMI 2026 Annual Meeting. The results show that ATNM-400 not only outperformed existing KRAS inhibitors but also demonstrated potent synergy with EGFR-targeting osimertinib, achieving complete tumor regression in models. This positions ATNM-400 as a prospective mutation-agnostic therapy in non-small cell lung cancer (NSCLC), addressing a significant portion of cases where traditional mutation-specific therapies fall short. The data reinforces Actinium's strategy to develop a broadly effective treatment capable of overcoming tumor resistance.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Actinium Pharmaceuticals presented new radiochemistry data at the SNMMI 2026 Annual Meeting, showcasing the benefits of optimizing the chelator-to-antibody ratio (CAR) in Actinium-225 radioconjugates. The study found that lower-CAR conjugates maintained effective tumor targeting while decreasing off-target uptake in the liver and spleen, thus broadening the therapeutic window. These results underscore Actinium's advanced radiochemistry capabilities and the implications for enhancing the safety and effectiveness of their drug candidates. The findings may significantly influence the design of future radioconjugates in their pipeline.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Actinium Pharmaceuticals has appointed Dr. Steffen Heeger as Chief Medical Officer to enhance its development pipeline. Dr. Heeger comes with significant experience in oncology and has been instrumental in successful drug approvals, including the blockbuster Erbitux®. His leadership is anticipated to advance Actinium's projects, including Actimab-A and ATNM-400, as the company prepares for critical clinical trials in the latter half of 2026. Actinium aims to leverage Dr. Heeger's expertise to further its goal of creating effective targeted radiotherapies.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Actinium Pharmaceuticals has received Notices of Allowance for two patent applications from the Canadian Intellectual Property Office, enhancing its intellectual property protection for the Actimab-A and Iomab-ACT programs. These patents cover innovative treatments for hematologic malignancies and gene-edited cell-based therapies. The company aims to expand its global patent estate, which now includes approximately 250 patents.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
Actinium Pharmaceuticals announced an update on its ATNM-400 program, showcasing new data at the SNMMI 2026 Annual Meeting. The presentations will highlight ATNM-400's efficacy in treating prostate cancer and non-small cell lung cancer. Additionally, the company received a notice from NYSE American regarding non-compliance with listing standards, prompting the need for a compliance plan.
Read more →ATNMActinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
Actinium Pharmaceuticals announced three upcoming presentations at the SNMMI 2026 Annual Meeting, showcasing the potential of ATNM-400 in treating non-small cell lung cancer (NSCLC) and prostate cancer. The data highlights ATNM-400's ability to function as a mutation-agnostic therapy and its effectiveness in PSMA-negative prostate cancer. Additionally, advancements in the radioconjugate's optimization are expected to enhance its therapeutic index.
Read more →ATNM▼ -7.9%on this news· ran to -20% by day 3
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Actinium Pharmaceuticals highlighted the anti-leukemic activity of Actimab-A at the AACR Annual Meeting, emphasizing its mutation-agnostic approach in treating acute myeloid leukemia (AML). Data indicated that Actimab-A combinations led to significant AML cell killing, independent of mutation status, by promoting transcriptional reprogramming. The findings suggest enhanced efficacy when paired with standard-of-care therapies, reinforcing Actimab-A's potential as a universal combination backbone in AML treatment. Additionally, the safety profile observed in previous clinical studies supports its further development as a foundational therapy.
Read more →ATNM▼ -7.9%on this news· ran to -20% by day 3
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Actinium Pharmaceuticals, Inc. has announced promising preclinical data for its novel targeted radiotherapy, ATNM-400, presented at the American Association for Cancer Research Annual Meeting. The data demonstrates the treatment's broad efficacy across various cancer models, including prostate, lung, and breast cancers, outperforming existing therapies in several cases. Notably, ATNM-400 is well tolerated with no significant toxicities observed, enhancing its development potential. The findings suggest that ATNM-400 could provide new options for patients with treatment-resistant tumors.
Read more →ATNM▲ +11.2%on this news
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Actinium Pharmaceuticals has announced new preclinical data for ATNM-400 and Actimab-A, highlighting their potential in treating solid tumors and acute myeloid leukemia (AML), respectively. The data will be presented at the AACR Annual Meeting 2026 in San Diego, showcasing ATNM-400's activity against tumors resistant to targeted therapies and Actimab-A's mutation-agnostic efficacy. Both compounds are positioned to provide significant advancements in cancer treatment, with presentations scheduled for April 21, 2026. The findings are part of Actinium's broader strategy to develop innovative radiotherapies.
Read more →ATNMActinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Actinium Pharmaceuticals, Inc. (ATNM) has announced the presentation of two abstracts at the 2026 AACR Annual Meeting, scheduled for April 17-22 in San Diego. The presentations will focus on the company's innovative targeted radiotherapies, particularly the ATNM-400 program which targets various cancers including prostate, lung, and breast cancers. The event marks an important opportunity for Actinium to engage with the oncology research community, showcasing their progress in differentiated radiotherapy development. Specific abstract details will be released on March 17, 2026, in accordance with AACR guidelines.
Read more →ATNMActinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
Actinium Pharmaceuticals presented new preclinical data for ATNM-400 at the 2025 SABCS, showcasing its strong anti-tumor activity against various breast cancer subtypes, including hormone receptor-positive and triple-negative cancers. The data highlight ATNM-400's potential as a treatment option for patients resistant to standard therapies. The findings support further development of ATNM-400 as a monotherapy or in combination with other treatments.
Read more →ATNMActinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
Actinium Pharmaceuticals announced promising preclinical data for ATNM-400, a targeted radiotherapy for triple-negative breast cancer and other types. The data, to be presented at the San Antonio Breast Cancer Symposium, indicates strong anti-tumor effects in models resistant to standard therapies. ATNM-400's unique mechanism may offer new hope for patients with limited treatment options.
Read more →ATNMActinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Actinium Pharmaceuticals will present new preclinical data for ATNM-400 at the 2025 San Antonio Breast Cancer Symposium. The data highlights the efficacy of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, as well as its potential across prostate cancer and non-small cell lung cancer. This therapy aims to address significant unmet needs in these oncology indications.
Read more →ATNMActinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
Actinium Pharmaceuticals, Inc. announced that its CEO, Sandesh Seth, will participate in the Stephens Biotechnology Virtual Fireside Chat on November 4, 2025. The event will also provide opportunities for one-on-one meetings with investors. Actinium is known for its targeted radiotherapies, including its lead candidate ATNM-400, which shows promise in treating prostate cancer and non-small cell lung cancer.
Read more →ATNM▼ -8.4%on this news
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals announced promising preclinical data for ATNM-400, a novel radioconjugate targeting non-small cell lung cancer (NSCLC). The data presented at the AACR-NCI-EORTC conference showed that ATNM-400 exhibited superior efficacy, achieving 3-5 times greater tumor growth inhibition compared to existing therapies. Additionally, the combination of ATNM-400 with osimertinib resulted in complete tumor regression in all tested subjects, highlighting its potential as a first-in-class treatment.
Read more →ATNM▲ +5.7%on this newsshared move
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals presented promising preclinical data for ATNM-400 at the 32nd Annual Prostate Cancer Foundation Scientific Retreat. This first-in-class radiotherapy targets a novel antigen and demonstrated superior efficacy compared to PSMA-targeted therapies. Notably, ATNM-400 achieved complete tumor regression in a significant percentage of animal models, showcasing its potential in treating resistant prostate cancer.
Read more →ATNMActinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals announced that preclinical data for ATNM-400 in non-small cell lung cancer (NSCLC) will be presented at the AACR-NCI-EORTC conference. This first-in-class Actinium-225 radiotherapy shows promise in overcoming resistance to osimertinib, potentially transforming treatment for patients with EGFR-mutant NSCLC. The drug also demonstrates significant efficacy in prostate cancer.
Read more →ATNM▲ +10.3%on this newsshared move
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals announced that preclinical data for ATNM-400 will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat. This first-in-class antibody radioconjugate demonstrates significant anti-tumor activity in metastatic castration-resistant prostate cancer, particularly in cases resistant to standard therapies. The data suggests ATNM-400 may offer a promising treatment option for patients facing limited choices.
Read more →ATNMActinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
Actinium Pharmaceuticals presented promising preclinical data for ATNM-400 at the 4th Annual Targeted Radiopharmaceuticals Summit. The data indicates that ATNM-400 significantly improves survival in prostate cancer models resistant to Pluvicto® and enzalutamide. The therapy demonstrated enhanced efficacy, achieving complete cures in a notable percentage of treated animals. Further evaluations are expected in the second half of 2025.
Read more →ATNMActinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals presented new preclinical data for ATNM-400 at the SNMMI annual meeting, highlighting its superior efficacy in killing prostate cancer cells compared to enzalutamide (Xtandi) and its ability to overcome resistance to existing therapies. The data suggests ATNM-400 could fill critical gaps in prostate cancer treatment, potentially improving patient outcomes. The company emphasizes its commitment to advancing this promising candidate.
Read more →ATNMActinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
Actinium Pharmaceuticals has enrolled the first patient in its Iomab-ACT trial at the University of Texas Southwestern Medical Center. This trial aims to evaluate Iomab-ACT as a targeted radiotherapy conditioning agent for CAR-T therapy, with initial data expected in late 2025. The approach seeks to reduce toxicities associated with traditional chemotherapy conditioning, potentially enhancing patient outcomes.
Read more →ATNMActinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Actinium Pharmaceuticals presented promising data on Actimab-A at the AACR Annual Meeting, highlighting its mutation agnostic activity against various mutations in acute myeloid leukemia (AML). The results indicate that Actimab-A, used with other standard therapies such as hypomethylating agents and targeted inhibitors, led to significant antileukemic effects in preclinical models. The company is advancing multiple clinical trials, aiming to demonstrate Actimab-A's potential for patients with high unmet health needs.
Read more →ATNMActinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
Actinium Pharmaceuticals has presented promising preclinical data on its product ATNM-400 at the AACR Annual Meeting, indicating that it may be a superior treatment option for prostate cancer compared to existing therapies like Pluvicto. The studies revealed that ATNM-400 inhibits tumor growth significantly and maintains efficacy even in cases where Pluvicto has failed. Additionally, ATNM-400 was well tolerated in models with no observable toxicities. This innovative candidate targets a receptor that is highly expressed in castration-resistant prostate cancer, offering a new approach for patients with unmet clinical needs.
Read more →ATNMActinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Actinium Pharmaceuticals has announced ATNM-400, a novel, non-PSMA targeting radiotherapy for prostate cancer, which utilizes the radioisotope Actinium-225. Initial preclinical results demonstrate significant tumor growth inhibition, with a single dose achieving up to 99.8% inhibition in model studies. The drug shows selective tumor uptake with minimal impact on healthy tissues. Further data will be presented at the upcoming AACR Annual Meeting, focusing on its efficacy against Pluvicto-resistant prostate cancer models.
Read more →ATNMActinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
Actinium Pharmaceuticals has unveiled ATNM-400, a first-in-class Actinium-225 radiotherapy targeting prostate cancer, during a business update presented at the Trump Mar-A-Lago Club. The company aims to enhance its clinical pipeline by establishing in-house manufacturing capabilities in 2025 and anticipates significant clinical data across multiple trials by the second half of 2025. Additionally, Actinium is focusing on various treatment programs for myeloid malignancies, solid tumors, and cell and gene therapies, highlighting its ambition to create multiple blockbuster opportunities. The financial outlook remains strong, with sufficient cash reserves for ongoing development.
Read more →ATNM▲ +18.4%on this newsshared move
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
Actinium Pharmaceuticals announced a business update presentation at the Trump Mar-a-Lago Club, showcasing advancements in its Actimab-A and Iomab-ACT clinical programs. The company is targeting multi-billion-dollar market opportunities across myeloid malignancies, solid tumors, and cell & gene therapy conditioning. With significant milestones expected in 2025, Actinium's Chairman expressed optimism about the potential for blockbuster market opportunities. Additionally, the company is enhancing its radiopharmaceutical manufacturing infrastructure to support its expanding capabilities.
Read more →ATNM▲ +6%on this news· ran to +26% by day 1shared move
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
Actinium Pharmaceuticals is hosting an investor call to discuss updated clinical programs including Actimab-A and Iomab-A's roles in various cancer treatments. Dr. Ehab Atallah will present promising clinical results for Actimab-A, focusing on its application in acute myeloid leukemia (AML) and its combination treatment with PD-1 inhibitors for solid tumors. The company also highlights significant market potential and plans for future trials under the National Cancer Institute's collaboration. Key developmental efforts aim to advance their therapies, projecting growth opportunities in targeted radiotherapies.
Read more →ATNMActinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Actinium Pharmaceuticals has announced a supply agreement with Eckert & Ziegler for Actinium-225 (Ac-225), which will support the development of Actimab-A and other candidates. This agreement will facilitate access to a reliable supply of Ac-225, crucial for ongoing U.S. and international clinical trials. Actimab-A targets CD33, offering potential benefits for patients with acute myeloid leukemia and aims to combine with PD-1 checkpoint inhibitors for treating various cancers. Actinium is committed to expanding its clinical pipeline to address significant medical needs.
Read more →ATNM▲ +16.5%on this news· ran to +31% by day 3shared move
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A
Actinium Pharmaceuticals has entered into a research collaboration with Memorial Sloan Kettering Cancer Center to advance the study of Actimab-A. This partnership aims to explore Actimab-A in conjunction with targeted therapies for acute myeloid leukemia (AML). The research will focus on assessing transcriptional profiles and treatment activity in AML patient samples. Through this collaboration, Actinium seeks to enhance the therapeutic potential and outcomes for AML patients.
Read more →ATNMActinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
Actinium Pharmaceuticals is set to host an investor call featuring Dr. Ehab Atallah to discuss progress on its drug Actimab-A and provide pipeline updates. The company highlights significant multi-billion-dollar market prospects for Actimab-A and Iomab-ACT, particularly in myeloid malignancies and solid tumors. Initial clinical data is anticipated by the end of 2025, including trials in combination with major immunotherapies. Actinium remains optimistic about advancing its clinical programs and maintaining a strong cash position through 2027.
Read more →ATNM▼ -8.5%on this news· ran to +19% by day 3shared move
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
Actinium Pharmaceuticals has announced a new clinical trial program evaluating its lead product Actimab-A in combination with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO. The trials aim to address the limitations of PD-1 inhibitors caused by Myeloid Derived Suppressor Cells (MDSCs) in solid tumors. Initial results are expected in 2025, with Actinium anticipating a significant market opportunity if outcomes are favorable. The targeted indications include Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer, involving a large patient population.
Read more →ATNM▲ +5.7%on this newsshared move
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Actinium Pharmaceuticals announced the publication of trial results for Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML) in the journal Leukemia. The study reported a median overall survival of 18.4 months in patients who had received previous therapies, outperforming historical data with CLAG-M alone. The trial demonstrated promising outcomes, particularly in high-risk patients with TP53 mutations, and showed a high rate of measurable residual disease negativity. Following these results, Actinium plans to commence a pivotal Phase 2/3 trial in 2025 to further investigate the efficacy of this treatment combination.
Read more →ATNMActinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium Pharmaceuticals, Inc. will participate in the 37th Annual Roth Conference from March 16th to 18th. The company is focused on developing targeted radiotherapies, with its lead candidate Actimab-A showing potential in acute myeloid leukemia. Actinium is collaborating with the National Cancer Institute for further clinical evaluations. The company continues to expand its pipeline and maintain a strong patent portfolio.
Read more →ATNMActinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology
Actinium Pharmaceuticals has launched a clinical trial evaluating a triplet combination of Actimab-A, Venetoclax, and ASTX-727 for frontline treatment in acute myeloid leukemia (AML). This unique combination aims to improve remission rates and outcomes in patients, particularly those with poor responses to existing therapies. The trial, endorsed by previous Phase 1 studies, marks a significant step in translating Actimab-A's development into broader clinical applications. The first clinical data is anticipated in the second half of 2025, potentially establishing Actimab-A as a frontline therapy for AML.
Read more →ATNM▼ -5.3%on this news
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
Actinium Pharmaceuticals reported significant advancements in its antibody radiation conjugate programs during the third quarter of 2024. The company aligned with the FDA on a seamless Phase 2/3 trial for Actimab-A and gained participation in the NCI's myeloMATCH program. Actinium announced the clearance of two INDs for Iomab-ACT, with expected clinical data by 2025. Financially, the company is in a strong position, with cash reserves projected to last into 2027, although a reduction in workforce raises concerns about operational impacts.
Read more →ATNMActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - Dr. Almenoff brings more than 25 years of drug development and leadership experience to t
Actinium Pharmaceuticals has appointed June Almenoff, M.D., Ph.D., to its Board of Directors. Dr. Almenoff has over 25 years of experience in the biopharmaceutical sector, including significant roles in leading development and commercialization efforts. With prior leadership experience at companies like Furiex Pharmaceuticals and RedHill Biopharma, she is expected to lend her expertise in translational medicine and regulatory processes to enhance Actinium's strategic goals. The appointment reflects Actinium's commitment to strengthening its leadership in the development of targeted radiotherapies.
Read more →ATNMActinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Actinium Pharmaceuticals announced the publication of the Phase 3 SIERRA trial results for Iomab-B, a novel radiotherapy for treating relapsed or refractory Acute Myeloid Leukemia (AML). The trial demonstrated significant improvements in durable Complete Remission and Event-Free Survival compared to conventional treatments. Despite these promising results, the trial did not meet the overall survival endpoint necessary for a Biologics License Application (BLA) filing with the FDA. Actinium plans to seek a strategic partner for further development and has ongoing discussions with the FDA regarding additional trials.
Read more →ATNM▼ -59.8%on this news
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. - FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistica
Actinium Pharmaceuticals announced that the FDA has deemed the Phase 3 SIERRA trial insufficient for a Biologics License Application (BLA) filing for Iomab-B, despite meeting its primary endpoint. The FDA has requested an additional randomized clinical trial demonstrating an overall survival benefit for the treatment. Actinium plans to engage with the FDA for further discussions and is also looking for strategic partnerships to advance Iomab-B post-FDA interactions, while continuing to focus on other programs and pipeline candidates.
Read more →ATNMActinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
Actinium Pharmaceuticals announced the issuance of U.S. Patent No. 11,912,780, which enhances its existing patent coverage for Iomab-ACT, a targeted radiotherapy conditioning agent. This patent pertains to its use with genetically engineered stem cells for non-malignant diseases, including sickle cell disease and β-thalassemia. The company aims to establish Iomab-ACT as a universal conditioning regimen for cell and gene therapies, demonstrating a commitment to innovation while addressing the toxicities associated with traditional chemotherapy. Clinical trials of Iomab-ACT have shown promising preliminary data, suggesting its potential efficacy and safety.
Read more →ATNMActinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Actinium Pharmaceuticals is set to present at the 3rd Annual Targeted Radiopharmaceuticals Summit in San Diego from July 30 to August 1, 2024. The presentation will focus on the promising outcomes of Iomab-B and Actimab-A, particularly in patients with challenging acute myeloid leukemia (AML) conditions, including TP53 mutations. Data will illustrate the efficacy of these therapies in enabling bone marrow transplants and how they can be effectively combined with other targeted treatments to improve patient responses. Actinium aims to further develop these innovative therapies to enhance survival rates in oncology.
Read more →ATNMActinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
Actinium Pharmaceuticals has received FDA clearance for its Investigational New Drug application to study Iomab-ACT as a targeted conditioning agent for sickle cell disease patients undergoing bone marrow transplants. This trial, conducted in collaboration with Columbia University, aims to evaluate the safety and efficacy of Iomab-ACT, which could potentially minimize the toxic effects associated with traditional chemotherapy. If successful, the approach may provide broader access to potentially curative gene therapies for sickle cell disease, addressing a significant unmet medical need.
Read more →ATNMActinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actinium Pharmaceuticals has presented groundbreaking preclinical data at the 2024 EHA Congress showing that Actimab-A combined with leading menin inhibitors leads to enhanced anti-tumor effects in acute myeloid leukemia (AML) models. This combination showed increased cell death and tumor elimination compared to monotherapies. Actimab-A, designed to target CD33, may expand its use as a backbone treatment in AML, supporting its potential across various phases of AML care. The encouraging results point towards future studies to explore this combination further.
Read more →ATNMActinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals presented promising results from the Phase 3 SIERRA trial of Iomab-B for acute myeloid leukemia patients with TP53 mutations at the EHA 2024 Congress. Patients receiving Iomab-B experienced a median overall survival of 5.49 months compared to 1.66 months for those who did not. Additionally, 75% of Iomab-B patients achieved complete remission, significantly outperforming the control arm, where only 6.3% achieved this outcome. The trial results underscore Iomab-B's potential to improve treatment outcomes for high-risk patients.
Read more →ATNMActinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals presented promising results from its Phase 1b trial of Actimab-A combined with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 SNMMI Annual Meeting. The trial demonstrated high overall response rates and significant measurable residual disease negativity, particularly among high-risk patient groups, such as those with TP53 mutations. Moreover, the therapy showed a favorable safety profile with no significant organ toxicity, further underscoring its potential as a treatment option. A notable portion of patients were able to proceed to bone marrow transplants, contributing to improved survival statistics.
Read more →ATNMActinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals presented promising data for Iomab-B at the 2024 SNMMI Annual Meeting, demonstrating improved survival rates in patients with TP53 mutations in acute myeloid leukemia. The Phase 3 SIERRA trial highlighted Iomab-B's capability to achieve high doses of targeted radiation safely and effectively. Additionally, the company showcased novel linker technology which supports the advancement of their antibody radiation conjugate pipeline in solid tumors. These developments underscore Actinium's commitment to improving treatments for patients with high-risk hematologic cancers.
Read more →ATNMActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals will host a KOL webinar on May 20, 2024, to discuss its Iomab-ACT commercial CAR T-cell therapy trial, which aims to enhance conditioning prior to cell and gene therapies. The trial at the University of Texas Southwestern represents a pivotal stage for Iomab-ACT as it is the first to study this targeted radiotherapy conditioning agent with an FDA-approved CAR T-cell therapy. Initial phase 1 trial results are promising, demonstrating a favorable safety profile and the potential for improved patient outcomes in blood cancer treatments.
Read more →ATNM▲ +11.6%on this newsshared move
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced promising results from the Phase 3 SIERRA trial of Iomab-B, showing improved survival outcomes in patients with TP53 mutations. Patients receiving Iomab-B led bone marrow transplants had a median overall survival of 5.49 months, significantly better than the 1.66 months observed in those not receiving the treatment. The trial also indicated high event-free survival rates among older patients with acute myeloid leukemia. Results will be presented at the European Hematology Association's 2024 congress in Madrid.
Read more →ATNMActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals has announced that five abstracts showcasing its Antibody Radiation Conjugates Iomab-B and Actimab-A, as well as novel linker technology, have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting. The presented data is expected to highlight improved survival rates of targeted radiotherapies for patients with relapsed/refractory acute myeloid leukemia. These developments indicate significant advancements in the treatment landscape for challenging cancers. CEO Sandesh Seth emphasized the potential of targeted radiation therapies to aid patients with difficult-to-treat conditions.
Read more →ATNMActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Actinium Pharmaceuticals is hosting a KOL webinar on May 20, 2024, to discuss its Iomab-ACT trial in conjunction with an FDA-approved CAR-T cell therapy at the University of Texas Southwestern. This advancement signifies a crucial step in utilizing Iomab-ACT, an antibody radiation conjugate, for conditioning prior to cell and gene therapies. Initial trial results have indicated significant safety advantages, including minimal incidences of common toxicities associated with existing CAR-T therapies. The market potential for this innovative approach is substantial, particularly in the context of expanding cellular therapy applications.
Read more →ATNM▼ -8%on this news
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals presented results from the Phase 3 SIERRA trial at the recent European Bone Marrow Transplant Annual Meeting, highlighting the efficacy of Iomab-B in treating high-risk, active relapsed refractory acute myeloid leukemia (AML) patients, especially those with TP53 mutations. The data revealed a median overall survival of 5.49 months for patients with TP53 mutations receiving Iomab-B, compared to just 1.66 months for those who did not. Furthermore, 55.56% of TP53 positive patients achieved complete remission with Iomab-B, showcasing its potential as a groundbreaking treatment. These findings emphasize Iomab-B's ability to improve survival in a patient population with limited therapeutic options.
Read more →ATNM▲ +9.3%on this news
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results for its therapy Iomab-B have been accepted for oral presentation at the 50th Annual European Bone Marrow Transplant Society meeting. The trial, which included patients with TP53 mutations, showed that Iomab-B significantly improved access to bone marrow transplant and achieved durable complete remission. Dr. Hannah Choe will present the results at the conference, highlighting the study's promising implications for treating high-risk acute myeloid leukemia patients.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Actinium Pharmaceuticals has announced a clinical trial led by UT Southwestern Medical Center to study its targeted radiotherapy agent Iomab-ACT as a conditioning regimen prior to FDA-approved CAR T-cell therapy. This innovative approach aims to replace traditional chemotherapy conditioning methods, potentially reducing toxicities such as ICANS and CRS. The trial is set to recruit patients following FDA clearance, with initial data showing promising results in terms of safety and efficacy. The CAR T-cell therapy market is anticipated to grow significantly, enhancing the relevance of Actinium's Iomab-ACT in improving patient outcomes.
Read more →ATNM▼ -9.5%on this news
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Actinium Pharmaceuticals has launched a strategic initiative to manufacture Actinium-225 using its proprietary cyclotron-based technology. This new method promises identical radiochemical purity to existing production standards while being significantly more cost-effective at scale. Actinium's strong patent portfolio supports this initiative, which aims to address the increasing demand for this critical medical isotope for cancer therapies. With prior successful production at scale, Actinium plans to enhance its production capabilities to ensure supply for its evolving product pipeline.
Read more →ATNM▲ +21.1%on this news
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Actinium Pharmaceuticals announced results from the Phase 3 SIERRA trial at the 2024 Tandem Meetings, showing that Iomab-B significantly improves long-term survival for patients aged 65 and older with active relapsed or refractory acute myeloid leukemia (r/r AML). The trial demonstrated a remarkable 100% access to bone marrow transplant, with treated patients achieving up to 2-year survival rates, while patients in the control group did not survive beyond one year. Additionally, Iomab-B showed efficacy in patients with high-risk features, including a TP53 mutation, marking an advancement in treatment options for this demographic. This underscores the potential of Iomab-B to meet unmet medical needs in oncology.
Read more →ATNMActinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Actinium Pharmaceuticals announced positive results from its Phase 3 SIERRA trial of Iomab-B, which significantly improved median overall survival in patients with TP53 positive relapsed refractory acute myeloid leukemia (AML). The study reported a median overall survival of 5.49 months for those treated with Iomab-B, compared to 1.66 months for patients receiving standard treatment. Additionally, more than 50% of treated patients achieved complete remissions. The findings were highlighted during presentations at the 2024 Tandem Meetings in San Antonio, Texas.
Read more →ATNMActinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Actinium Pharmaceuticals announced that five abstracts, including two oral and three poster presentations, have been accepted for the 2024 Tandem Meetings focused on transplantation and cellular therapy. The presentations will emphasize results from the successful Phase 3 SIERRA trial of Iomab-B, which aims to enhance outcomes for patients with high-risk relapsed/refractory acute myeloid leukemia. This marks a significant opportunity for Actinium to showcase their advancements to a specialized audience in San Antonio, Texas. The abstracts reflect Actinium's commitment to explore innovative therapies within the sector.
Read more →ATNM▼ -7.5%on this news
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Actinium Pharmaceuticals announced positive results from the Phase 3 SIERRA trial of Iomab-B, particularly highlighting improved survival rates for patients with TP53 mutations, known for poor outcomes. The data showed a median overall survival of 5.49 months for patients receiving Iomab-B, compared to 1.66 months for those who did not. Iomab-B achieved a durable complete remission (dCR) rate of 22% in treated patients, marking a significant advancement in therapy for relapsed or refractory acute myeloid leukemia (AML). The trial results were presented at the 65th Annual American Society of Hematology Meeting and further emphasize the potential of Iomab-B in improving patient access to curative treatments.
Read more →ATNM▼ -7.5%on this news
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
Actinium Pharmaceuticals presented four key studies at the 65th ASH Annual Meeting, showcasing the positive outcomes of their targeted radiotherapies Iomab-B and Actimab-A for patients with relapsed or refractory acute myeloid leukemia (AML). The Phase 3 SIERRA trial highlighted that Iomab-B significantly improved overall survival rates, particularly for patients with TP53 mutations. Additionally, Actimab-A demonstrated its potential effectiveness when used in combination with Venetoclax. The company plans to move forward with further regulatory filings and continued development of these therapies.
Read more →ATNMActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Actinium Pharmaceuticals is set to showcase the promising results of its targeted radiotherapies, Iomab-B and Actimab-A, at the upcoming 65th ASH Annual Meeting. Their presentations will emphasize improved survival rates for elderly patients with relapsed or refractory acute myeloid leukemia, particularly those with TP53 mutations. The company highlights the need for better treatment options in this patient population and is preparing for significant regulatory submissions. The data suggests Iomab-B and Actimab-A may effectively address high-risk cases of AML, indicating a strong potential for these therapies.
Read more →ATNMActinium Presents Preclinical Data at SITC Demonstrating Actimab-A
Actinium Pharmaceuticals presented promising preclinical data on Actimab-A at the SITC 38th Annual Meeting, highlighting its ability to target CD33 positive myeloid-derived suppressor cells (MDSCs) and enhance T cell responses. The data demonstrated significant reductions in MDSC viability and effective uptake in tumor environments during preclinical studies. This suggests Actimab-A could synergize with immunotherapies to improve outcomes in solid tumors with high unmet medical needs. The company continues to explore advancing Actimab-A's clinical development alongside other pipeline candidates.
Read more →ATNMActinium Appoints Lynn Bodarky as Chief Business Officer
Actinium Pharmaceuticals has appointed Lynn Bodarky as its new Chief Business Officer, bringing over 25 years of experience in business development from companies like Pfizer and Merck. Bodarky is set to lead the company's business development, licensing, and collaboration activities as Actinium advances its pipeline of targeted radiotherapies. The company is encouraged by recent positive clinical data and strategic partnerships that position it for growth in the competitive oncology market. Bodarky expressed excitement about joining Actinium and the potential to enhance business development opportunities within the organization.
Read more →ATNM▼ -15.5%on this newsshared move
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced promising results from its Phase 3 SIERRA trial of Iomab-B for relapsed or refractory acute myeloid leukemia patients with TP53 mutations. The data showed a significant increase in median overall survival for these patients, with a hazard ratio of 0.23. The results will be presented at the upcoming ASH Annual Meeting, highlighting the potential of Iomab-B as a treatment option for a population with limited existing therapies. Additionally, financial updates indicate an increase in research expenses, reflecting investment in future growth and development.
Read more →ATNM▼ -15.5%on this newsshared move
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Actinium Pharmaceuticals, Inc. announced its attendance at Bio-Europe Munich 2023, the largest biopharmaceutical industry partnering event in Europe, taking place from November 6-8. The company is advancing a pipeline of targeted radiotherapies, including Iomab-B, which has met its primary endpoint in a Phase 3 trial and is preparing for a BLA filing. Additionally, Actinium is developing Iomab-ACT for cell and gene therapy and Actimab-A for acute myeloid leukemia, showcasing their innovative approaches in oncology. Leadership will be available for one-on-one meetings during the event.
Read more →ATNMActinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering
Actinium Pharmaceuticals has announced the extension of a NIH grant to further its clinical collaboration with Memorial Sloan Kettering Cancer Center for Iomab-ACT, a next-generation CD45-targeting conditioning agent. This initiative is significant as it aims to combine Iomab-ACT with CAR-T cell therapy to improve lymphodepletion and minimize side effects such as cytokine release syndrome. The treatment holds the promise of enhancing accessibility to cellular and gene therapies for patients with difficult-to-treat blood cancers, significantly altering treatment paradigms.
Read more →ATNMActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
Actinium Pharmaceuticals announced that an abstract has been accepted for a poster presentation at the SITC 38th Annual Meeting scheduled for November 3-5, 2023. The abstract focuses on the preclinical evaluation of lintuzumab-Ac225, addressing treatment for myeloid-derived suppressor cells. Actinium's ongoing development of targeted radiotherapies aims to enhance survival rates, particularly in patients with relapsed and refractory acute myeloid leukemia. The company is also progressing with other pipeline candidates and has established collaborations with several notable pharmaceutical companies.
Read more →ATNMActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
Actinium Pharmaceuticals presented updated survival data from its Actimab-A + CLAG-M trial at the SOHO 2023 Annual Meeting, highlighting a median overall survival of 30 months for patients with prior venetoclax treatment. In this study, Actimab-A was also shown to enhance the activity of certain FLT3 inhibitors, with preclinical data supporting further exploration for this combination approach. The company emphasized the need for effective therapeutic options for patients with acute myeloid leukemia who experience disease relapse after venetoclax treatment. Additionally, results from the completed Phase 3 SIERRA trial of Iomab-B were shared, showcasing ongoing advancements in their treatment pipeline.
Read more →ATNMActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
Actinium Pharmaceuticals announced the acceptance of three abstracts for poster presentations at the upcoming SOHO 2023 Annual Meeting. The notable presentations will highlight data demonstrating the anti-leukemic effects of Actimab-A in FLT3 mutant acute myeloid leukemia models. Additionally, the studies will showcase the efficacy of Iomab-B in relapsed/refractory AML and the potential of Lintuzumab-Ac225 to improve patient survival. This marks a significant step in Actinium's commitment to advancing targeted radiotherapies for cancer treatment.
Read more →ATNMActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
Actinium Pharmaceuticals announced that two abstracts have been accepted for presentation at the EANM 2023 Congress in Vienna from September 9-13. The oral presentation will highlight the promising Iomab-B SIERRA data that may transform transplant options for patients with relapsed/refractory acute myeloid leukemia. Additionally, an e-poster will feature the feasibility of a high-dose radiation treatment in AML patients. This recognition at a leading medical conference underscores Actinium's advancements in targeted radiotherapies.
Read more →ATNMActinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
Actinium Pharmaceuticals, Inc. has announced its participation in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, where it will present on July 27, 2023. The presentation will focus on the potential of targeted radiotherapeutics and innovative combinations to improve treatment outcomes for various malignancies. The company is recognized for its development of therapies aimed at enhancing survival rates for patients who have failed existing cancer treatments. Actinium's pipeline includes promising candidates such as Iomab-B and Actimab-A.
Read more →ATNMSNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium
Actinium Pharmaceuticals, Inc. announced that their abstract on Iomab-B has been awarded the SNMMI 2023 Abstract of the Year. The abstract, which focuses on individualized dosing for treating relapsed/refractory acute myeloid leukemia (AML), emphasizes the potential of Iomab-B to facilitate access to bone marrow transplants for patients. With plans to file a Biologics License Application later this year, Actinium aims to bring this targeted radiotherapy to market, addressing the urgent needs of AML patients with limited treatment options.
Read more →ATNM▼ -6.9%on this newsshared move
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
Actinium Pharmaceuticals has announced that six of its abstracts have been accepted for presentation at the SNMMI 2023 Annual Meeting in Chicago, occurring from June 24-27, 2023. These presentations will cover advancements in targeted radiotherapies, highlighting their ongoing research and development efforts in cancer treatment. The focus is primarily on therapies for relapsed or refractory acute myeloid leukemia, with indications of meaningful improvement in patient outcomes. The presentations will include important sessions discussing dosing, safety, and effectiveness derived from their pivotal phase 3 SIERRA trial.
Read more →ATNMActinium Pharma to Present at the Maxim Healthcare Virtual Conference
Actinium Pharmaceuticals, Inc. will showcase its advancements in targeted radiotherapies at the Maxim Healthcare Virtual Conference scheduled for June 21, 2023. The company is recognized for developing treatments aimed at improving patient outcomes in oncology, particularly before bone marrow transplants. Notably, Actinium's lead candidate, Iomab-B, has displayed promising results in clinical trials, thereby enhancing its profile in the biopharmaceutical sector.
Read more →ATNMActinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit
Actinium Pharmaceuticals, Inc. will participate in the TD Cowen Radiopharmaceutical Innovation Summit on June 20, 2023, where the company will engage in a fireside chat. This presentation will focus on Actinium's advancements in targeted radiotherapy treatments, particularly the promising results of their lead candidate, Iomab-B, in clinical trials. Iomab-B has shown significant potential in improving outcomes for patients undergoing bone marrow transplants. The event will be accessible through a live webcast and can be replayed for up to 30 days post-event.
Read more →ATNMActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
Actinium Pharmaceuticals announced positive results from its pivotal Phase 3 SIERRA trial for Iomab-B, a targeted radiotherapy for older patients with relapsed/refractory acute myeloid leukemia. The trial showed significant improvements in durable complete remission rates and overall survival. Iomab-B not only safely delivered myeloablative doses of targeted radiation but also improved patient access to bone marrow transplants. A Biologics License Application (BLA) filing for Iomab-B is anticipated by year's end 2023 based on these encouraging trial outcomes.
Read more →ATNM▲ +5.5%on this newsshared move
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
Actinium Pharmaceuticals, Inc. announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective June 23, 2023. This addition is significant for Actinium as these indexes are widely utilized benchmarks by institutional investors. The company focuses on developing targeted radiotherapies aimed at treating cancers, primarily with its lead product candidate, Iomab-B. Recent clinical trials have demonstrated its effectiveness in improving treatment outcomes for patients with acute myeloid leukemia.
Read more →ATNMActinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium
Actinium Pharmaceuticals has announced that six abstracts have been accepted for both oral and poster presentations at the Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting. The abstracts cover various aspects of the company's clinical products, particularly Iomab-B and Actimab-A, indicating progress in targeted radiotherapies. Highlights include strong results from the SIERRA Phase 3 trial for Iomab-B in relapsed/refractory AML. The company is also exploring machine learning applications for optimizing dosimetry and has established collaborative efforts to enhance the development of its therapies.
Read more →ATNMActinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
Actinium Pharmaceuticals announced that an abstract detailing results from its SIERRA trial of Iomab-B has been accepted for oral presentation at the European Hematology Association Congress. This trial compared Iomab-B's effectiveness in older patients with relapsed or refractory acute myeloid leukemia to conventional care. The presentation emphasizes Iomab-B's potential for improving patient outcomes by facilitating bone marrow transplants for those deemed ineligible previously. This acceptance at a leading medical conference signals growing recognition of the drug's capabilities.
Read more →ATNMActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day
Actinium Pharmaceuticals, Inc. (ATNM) announced its participation in the Guggenheim Healthcare Talks Radiopharmaceuticals Day, where its management will deliver a presentation on May 15, 2023. The company is recognized for its development of targeted radiotherapies and has shown positive results in clinical trials, particularly with its lead candidate, Iomab-B, for treating acute myeloid leukemia. Actinium is also actively involved in partnerships to further advance their research and development in targeted radiotherapies.
Read more →ATNMActinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress
Actinium Pharmaceuticals announced successful administration of Iomab-B in the Phase 3 SIERRA trial at 24 major bone marrow transplant (BMT) centers. The trial demonstrated that nurses experienced minimal radiation exposure while administering the therapy, suggesting a safe implementation process. Actinium reported strong confidence in the scalability of Iomab-B usage following anticipated FDA approval, especially given the therapy's success in enabling previously ineligible patients to access BMT. The firm's educational efforts were pivotal in ensuring rapid proficiency among BMT staff administering Iomab-B.
Read more →ATNMActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
Actinium Pharmaceuticals presented positive results from its Phase 3 SIERRA trial of Iomab-B at the EBMT Annual Meeting. The trial demonstrated a remarkable 100% access to bone marrow transplants for patients with active relapsed or refractory acute myeloid leukemia. Iomab-B not only met its primary endpoint of durable Complete Remission but also yielded high survival rates, showcasing its potential effectiveness and safety. The presentation at EBMT is expected to enhance awareness and facilitate further market opportunities in Europe, where the demand for such treatments is significant.
Read more →ATNMActinium Presents Data Demonstrating Actimab-A
Actinium Pharmaceuticals presented promising data on Actimab-A at the AACR 2023 Annual Meeting, demonstrating its ability to deplete myeloid derived suppressor cells (MDSCs) more effectively than other CD33-targeted therapies. This depletion is significant as MDSCs play a role in immunosuppression in tumors, and the results suggest Actimab-A could enhance antitumor responses when used alongside other immunotherapies. The findings underscore the potential of Actimab-A in improving treatment outcomes for various cancers.
Read more →ATNMActinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
Actinium Pharmaceuticals announced promising data on its HER3-targeted radiotherapy at the AACR Annual Meeting, demonstrating significant anti-cancer activity in ovarian and colorectal cancer models. The conjugates, Actinium-225 and Lutetium-177, showed a highly significant reduction in tumor volume compared to existing treatments. HER3 is overexpressed in multiple solid tumors, indicating this approach could offer new treatment options across various cancer types. The findings reinforce Actinium's commitment to developing targeted therapies to address unmet medical needs.
Read more →ATNMActinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
Actinium Pharmaceuticals has reported encouraging results from its 2022 financial report, highlighting the positive outcomes from the Phase 3 SIERRA trial of Iomab-B for treating relapsed or refractory acute myeloid leukemia (r/r AML) patients aged 55 and over. The company plans to initiate an Early Access Program and file a Biologics License Application (BLA) in the second half of 2023 based on these results. Additionally, the combination therapy utilizing Actimab-A has demonstrated significant one- and two-year survival rates in patients who previously failed venetoclax treatment. Actinium's robust financial position is expected to support its operations and clinical developments through 2025.
Read more →ATNMActinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting
Actinium Pharmaceuticals, Inc. has announced that two abstracts highlighting their innovative therapies have been accepted for presentation at the AACR 2023 Annual Meeting. These presentations will showcase the anti-cancer activity of Actimab-A and the effectiveness of HER3-targeted radiotherapies in preclinical models of ovarian and colorectal cancers. The data presented aim to address unmet therapeutic needs in oncology and demonstrate Actinium's leadership in targeted radiotherapy innovation. Additionally, a recent collaboration with the NCI is set to advance the development of Actimab-A for various disease indications.
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at Oppenheimer
Actinium Pharmaceuticals, Inc. announced its participation in the Oppenheimer's 33rd Annual Healthcare Conference from March 13-17, 2023. During the virtual event, the company's management will highlight recent achievements, notably the positive outcomes from its pivotal Phase 3 SIERRA trial of Iomab-B and new development opportunities for Actimab-A in collaboration with the National Cancer Institute. The conference aims to showcase a diverse range of healthcare companies and foster discussions about upcoming industry advancements.
Read more →ATNM▲ +6.7%on this news
Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar
Actinium Pharmaceuticals announced a KOL webinar featuring Dr. Sergio Giralt, discussing the successful results from the Phase 3 SIERRA trial of Iomab-B for treating older patients with relapsed or refractory acute myeloid leukemia (r/r AML). The trial demonstrated significant efficacy, with plans for a Biologics License Application (BLA) submission in late 2023. Actinium's financial position is solid, with forecasted cash reserves to support operations through 2025, enhancing its potential to deliver impactful treatments to this patient population.
Read more →ATNM▼ -16.9%on this news· ran to -37% by day 1
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia - Iomab-B met the primary endpoint of durable Complete Remission
Actinium Pharmaceuticals announced positive results from its pivotal Phase 3 SIERRA trial, demonstrating that Iomab-B achieved durable Complete Remission (dCR) in 22% of patients after six months. The trial, focused on older patients with relapsed or refractory acute myeloid leukemia, showed significant improvements in survival rates and Event Free Survival (EFS). The results indicate a high potential for Iomab-B to be established as a new standard of care in treating this challenging patient population, with a favorable safety profile noted in the outcomes.
Read more →ATNMActinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023
Actinium Pharmaceuticals will present full results from its pivotal Phase 3 SIERRA trial of Iomab-B during an investor call following a late-breaker presentation at the 2023 Tandem Meetings. The SIERRA trial demonstrated positive topline results, achieving durable Complete Remission in patients with relapsed or refractory acute myeloid leukemia. Actinium plans to submit a Biologics License Application seeking approval to use Iomab-B for patients aged 55 and older who are unable to access Bone Marrow Transplant. The drug has been granted Orphan Drug Designation by the FDA and is targeted at improving patient outcomes in blood cancer treatments.
Read more →ATNMActinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies
Actinium Pharmaceuticals has announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to further develop Actimab-A for treating acute myeloid leukemia (AML) and other hematologic malignancies. The agreement allows NCI to sponsor and oversee clinical trials, with Actinium supplying the necessary product. This collaboration will also provide access to a vast network of clinical sites and could accelerate the development of novel combinations involving Actimab-A. The partnership is expected to enhance the clinical potential of Actimab-A in oncology treatments.
Read more →ATNM▲ +7.3%on this news
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference
Actinium Pharmaceuticals, Inc. announced its participation in the 3rd Annual B. Riley Securities Oncology Conference scheduled for January 19, 2023. The company's management will engage in a fireside chat during the event, which focuses on new therapies and advancements in oncology. Actinium is noted for its development of targeted radiotherapies, particularly in preparations for bone marrow transplants and treatments for Acute Myeloid Leukemia. Their lead product candidate has demonstrated positive clinical trial outcomes, reinforcing the company's position in the biopharmaceutical landscape.
Read more →ATNMActinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
Actinium Pharmaceuticals announced that data from its Phase 3 SIERRA trial of Iomab-B has been accepted for a late-breaker presentation at the upcoming Transplantation & Cellular Therapy Tandem Meetings. The SIERRA trial met its primary endpoint with high statistical significance, highlighting the efficacy of Iomab-B in older patients with relapsed or refractory acute myeloid leukemia. Additionally, Actinium plans to submit a Biologics License Application seeking approval for Iomab-B to improve access to bone marrow transplantation for eligible patients. Important discussions and presentations are planned around these results, including a conference call and webcast following the presentation.
Read more →ATNMActinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
- 59% 1-year overall survival and 32% 2-year overall survival in patients with prior Venetoclax treatment - 52% 1-year overall survival and 19% 2-year overall survival in patients with a TP53 mutation - 75% measurable residual disease negativity achieved in heavily pretreated,
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative
- Collaboration builds on the groundbreaking research of Columbia University oncologist Dr. Siddhartha Mukherjee that uses gene-editing to remove the CD33 surface protein from hematopoietic stem cells - Actimab-A to be used post-transplant of these engineered stem cells to preve
Read more →ATNM▼ -11.5%on this news· ran to -24% by day 1
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches Patients on study received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of p
Read more →ATNM▲ +8.8%on this newsshared move
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology -Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov.
Read more →ATNM▲ +39.2%on this newsshared move
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia - Iomab-B met the primary endpoint of durable complete remis
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia NEW YORK, NY - October 31, 2022 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a l
Read more →ATNMActinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
Key hires with proven expertise and track records in Bone Marrow Transplant, Acute Myeloid Leukemia, Radiation Sciences and Clinical Operations position Actinium well to drive key clinical programs forward NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (N
Read more →ATNM▲ +9.7%on this news· ran to +71% by day 3shared move
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today announced that it will be participating in the Bio-Europe conference being held virtually November
Read more →ATNM▲ +8.6%on this news· ran to +33% by day 3shared move
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan, Senior Vice President, Head of CMC and Product Development, joins from Bristol Myers Squibb, and significantly strengthens team with hig
Read more →ATNMActinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
NEW YORK, Sept. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today announced that it will present at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference,
Read more →ATNMActinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022 Additional updates on collaborations and pipeline progress demonstrating Actinium's leadership in t
Read more →ATNM▲ +8.9%on this news
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in the H.C. Wainwright 24th A
Read more →ATNMActinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
- Data from completed Iomab-B pivotal Phase 3 SIERRA trial demonstrate the potential of Iomab-B in enabling successful BMT in patients who cannot typically be transplanted - 5x greater magnitude of Iomab-B versus control arm patients potentially evaluable for the primary endpoin
Read more →ATNM▲ +6.5%on this news
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
- Updated Phase 3 SIERRA data to be presented in an oral presentation by Boglarka Gyurkocza, M.D., SIERRA trial investigator from Memorial Sloan Kettering Cancer Center - Iomab-B to be featured in a CME symposium event led by KOLs titled "Landmarks Across the Patient Journey in
Read more →ATNM▲ +24%on this news
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
-Potential for up to $452 million in milestone payments with royalties in the mid-twenty percent range -Actinium receives $35 million upfront payment -Immedica obtains exclusive rights to Iomab-B in Europe, the Middle East and North Africa NEW YORK and STOCKHOLM , April 12, 20
Read more →ATNMActinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
Data further expand Actinium's leadership in combining targeted radiotherapy with CD47 immunotherapy in solid tumors and blood cancers Significant increase in tumor control with the HER3 ARC magrolimab combination compared to magrolimab alone in HER3-expressing NSCLC in vivo mod
Read more →ATNMActinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
- Data show enhanced antitumor effects and improved survival were observed in a preclinical NSCLC model compared to a naked HER3 antibody - HER3 targeted radiotherapy represents a novel therapeutic strategy for tumors expressing HER3 and tumors with acquired resistance to HER1/2
Read more →ATNMActinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
NEW YORK and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), a commercial stage, oncology-focused biopharmac
Read more →ATNM▼ -7.4%on this news
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
NEW YORK and SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs and EpicentRx, Inc. ("EpicentRx"), a San Diego-based clini
Read more →ATNM▼ -7.1%on this news
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that updated data from the recently complete Actimab-A
Read more →ATNM▼ -7.1%on this news
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that data from the Phase 1 portion of its Actimab-A and
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that positive data from the fully enrolled pivotal Phas
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs announced today its participation in the Targeted Radiopharmaceuticals S
Read more →ATNMActinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting Actimab-A in combination with a
Read more →ATNMActinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting an anti-HER2 antibody radiation
Read more →ATNMActinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that the Phase 1 trial studying Actimab-A with the salv
Read more →ATNMActinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple abstracts highlighting its Iomab-B and Actimab
Read more →ATNMActinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that two abstracts featuring targeted radiotherapies in
Read more →ATNMActinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at the Cantor Fitzgerald Virtual
Read more →ATNMActinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium re
Read more →ATNM▲ +8.4%on this newsshared move
Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel - Arun Swaminathan, Ph.D. appointed as Ch
Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel NEW YORK, NY - September 23, 2021 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actiniu
Read more →ATNM▼ -5.5%on this newsshared move
Actinium to Present at Four Upcoming Investor Conferences
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at four upcoming investor confer
Read more →ATNM▲ +18.6%on this newsshared move
Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamist
Read more →ATNMActinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index
NEW YORK, June 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced today that it will be added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective aft
Read more →ATNMActinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate in the EU and Japan
NEW YORK, June 17, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase 3 candidate, Iomab-B, has been further strengthened internationally. In the EU
Read more →ATNMPivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference
NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an oral presentation at the 2021 Society of Nuclear Medicine and Molecular Imagin
Read more →ATNMSafety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference
NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) were presented
Read more →ATNMActinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting
NEW YORK, June 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Company's pivotal Phase 3 SIERRA trial for lead program Iomab-B, have been accept
Read more →ATNMActinium to Participate in the Cell & Gene Meeting on the Mediterranean
NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021, where it wil
Read more →ATNMActinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in
Read more →ATNMActinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer Center ("MSK"), has commenced patient enrollment in the Phase 1 study evaluating Ioma
Read more →ATNMActinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-based CD45-targeted Next-Generation conditioning agent has been accepted for po
Read more →ATNMActinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
NEW YORK, March 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Mark Kubik, MBA to the position of Chief Business Officer (CBO). In this role, Mr. Kubik will be responsible for leading the Company's busi
Read more →ATNMActinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
NEW YORK, March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Sciences Conference, which is being held digitally March 9-10, 2021. Members of Act
Read more →ATNMActinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (TCT) Annual Meeting, which is being held virtually from February 8th – 12th. T
Read more →ATNMActinium Announces Participation in BIO CEO & Investor Digital Conference
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 – 18, 2021. Members of Acti
Read more →ATNMActinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from Januar
Read more →ATNMActinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE
Read more →ATNMActinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the independent Data Monitoring Committee (DMC) has completed the single ad hoc interim analysis of the pivotal Phase 3 SIERRA study of
Read more →ATNMActinium Highlights Presence at Targeted Radiopharmaceuticals Summit
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Targeted Radiopharmaceuticals Summit being held virtually December 8th – 10th. During the event, Dale Lud
Read more →ATNMActinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
NEW YORK, Dec. 8, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in patients
Read more →ATNMActinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing pivotal Phase 3 trial in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were present
Read more →ATNMActinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing Actimab-A CLAG-M Phase 1 combination trial in relapsed or refractory Acute Myeloid Leukemia (AML) were pres
Read more →ATNMActinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (R/R
Read more →ATNMActinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted that four abstracts detailing the Company's clinical trials for Iomab-B and Actimab-A will be presented at the 62nd American Society of Hematology (ASH) Annu
Read more →ATNMActinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role,
Read more →ATNMActinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
NEW YORK, Nov. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apa
Read more →ATNMActinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
NEW YORK, Nov. 19, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Avinash Desai, MD, to the position of Executive Vice President of Clinical Development, Operations and Medical Affairs, effective immediate
Read more →ATNMActinium to Participate in the Alliance Global Partners
NEW YORK, Nov. 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, November 19, 2020. During the event, Actin
Read more →ATNMActinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will host a CD33 program update featuring two key opinion leaders (KOLs) today, November 11th at 4:15 PM ET. The event will feature KOLs Dr. Ehab Atal
Read more →ATNM100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisc
Read more →ATNMActinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology
Read more →ATNMActinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation at the 2020 American Soci
Read more →ATNMActinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today provided a corporate update covering the progress made in 2020 thus far as well as major milestones expected by year-end and in 2021. Sandesh Seth, Ac
Read more →ATNMOctober 2020 Dear Actinium Shareholder: In 2020 thus far, we have made steady progress with our Iomab-B SIERRA pivotal trial, which is in its final quartile of enrollment, and our Actimab-A combination trials in the Rela
Dear Actinium Shareholder: In 2020 thus far, we have made steady progress with our Iomab-B SIERRA pivotal trial, which is in its final quartile of enrollment, and our Actimab-A combination trials in the Relapsed and Refractory Acute Myeloid Leukemia (R/R AML) setting. We are o
Read more →ATNMActinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration wi
Read more →ATNMActinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capa
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venet
Read more →ATNMActinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today announced that it has successfully completed the first dosing cohort in the Actimab-A and venetoclax combination, multi-center Phase 1 trial for patie
Read more →ATNMActinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today provided an update on the Actimab-A CLAG-M combination Phase 1 trial being conducted at the Medical College of Wisconsin ("MCW") in patients with Rela
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment C
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Reverse Stock Split
Pharmaceuticals, Inc. Announces Reverse Stock Split YORK, NY - August 10, 2020 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding commo
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering
Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering YORK, NY - June 19, 2020 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of its previously announced public offering of 76,923,077 shares of
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Proposed Public Offering
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering NEW YORK, NY - June 16, 2020 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common stock (or common stock eq
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering
NEW YORK, June 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters
NEW YORK, April 24, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of the Company's previously announced underwritten public offering of 210,833,334 shares of common stock (or common stock equiva
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering
NEW YORK, April 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the pricing of the Company's previously announced underwritten public offering of 183,333,334 shares of common stock (or common stock equiva
Read more →ATNMActinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020
NEW YORK, April 16, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today provided an update on the Iomab-B pivotal SIERRA (Study of Iomab-B in Elderly Relapse or Refractory Acute Myeloid Leukemia) trial incorporating the im
Read more →ATNMActinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia
NEW YORK, March 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial. This Phase 1 trial is an investigator-init
Read more →ATNMActinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute mye
Read more →ATNMActinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
NEW YORK, Feb. 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today findings from the SIERRA trial that were presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT) in Orlando, FL. Dr. Bogla
Read more →ATNMActinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation
NEW YORK, Feb. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at the 2020 Transplantation & Cellular Therapy (TCT) Meetings™
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Innovation Organ
Read more →ATNMActinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma
NEW YORK, Jan. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to utilize Actinium's Antibody Radiation-Conjugate or ARC apamistam
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™
NEW YORK, Jan. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that Sandesh Seth, Actinium's Chairman and CEO, will present at the 2020 Biotech Showcase™ being held on January 13-15. The conference will be at the Hilton Sa
Read more →ATNMActinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting
NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy regimen CLAG-M that was presented in a poster presentation at t
Read more →ATNMActinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy
NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") presented new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) at the 2019 American Society of Hematology (ASH) annual meeting on Sunday, De
Read more →ATNMActinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference
NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will attend the 25th Annual BIO-Europe® International Partnering Conference being held November 11 – 13, 2019 at the Hamburg Messe in Hamburg, Germany.
Read more →ATNMActinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) that support its Iomab-ACT program for lymphodepletion for CAR-T a
Read more →ATNMActinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been accepted for presentation at the 2019 American Society of Hem
Read more →ATNMActinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including feasibility and safety data, at 50% of total patient enrollment. The SIERRA t
Read more →ATNMActinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th
NEW YORK, Oct. 24, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will a host a conference call and webcast to highlight interim results from the pivotal Phase 3 SIERRA trial for its lead program, Iomab-B. The SIERRA
Read more →ATNMActinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa
NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene Meeting on the Mesa being held October 2nd – October 4th in Carlsbad, CA. Members of Actinium's executive and
Read more →ATNMActinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts
NEW YORK, Sept. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was awarded Honorable Distinction at the 2019 SOHO (Society of Hemat
Read more →ATNMActinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment. The forum is being held at the Congress Center Base
Read more →ATNMActinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference
NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), today announced that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference. The conference is being held at the Lotte New York Palace Hotel in New
Read more →ATNMActinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
NEW YORK, July 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that the 75th patient has been treated in the pivotal Phase 3 SIERRA trial of Iomab-B, thus achieving 50 percent patient enrollment for the trial. The SIERRA
Read more →ATNMActinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers
NEW YORK, July 11, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted its presence at the Health Physics Society ("HPS") 64th Annual Meeting that is being held July 7th – 11th in Orlando, Florida. During HPS, Actinium presente
Read more →ATNMActinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
NEW YORK, June 26, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that a poster detailing Actinium's preclinical work with the CD38 antibody daratumumab, a blockbuster therapy marketed as Darzalex® by Johnson & Johnson for p
Read more →ATNMActinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
NEW YORK, June 25, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced at SNMMI or the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting that effective lymphodepletion with the radioisotope Lu-177 or lutetium-
Read more →ATNMActinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ( Actinium ) today announced its presence at the upcoming SNMMI or Society of Nuclear Medicine...
NEW YORK, June 20, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced its presence at the upcoming SNMMI or Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting being held June 22nd – 25th in Anaheim, California
Read more →ATNMActinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
NEW YORK, June 4, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") presented new data from the ongoing pivotal Phase 3 SIERRA study of Iomab-B's single agent effect in patients with active, relapsed or refractory AML or Acute Myeloid Leukemia
Read more →ATNMAbstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
NEW YORK, May 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at
Read more →ATNMActinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
NEW YORK, May 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Niva Almaula, Ph.D. as Chief Business Officer, effective immediately. Dr. Almaula joins Actinium with significant experience in the targeted
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
NEW YORK, April 18, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the pricing of an underwritten public offering of 42,860,000 shares of its common stock at a combined public offering price of $0.385 per share of common sto
Read more →ATNMPharmaceuticals, Inc.
Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants NEW YORK, NY - April 17, 2019 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, sh
Read more →ATNMActinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEW YORK, April 17, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its commo
Read more →ATNMActinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium...
NEW YORK, April 8, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 – 4, 2019 in Ottawa, Canada. Two oral and four poster presen
Read more →ATNMActinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
NEW YORK, April 3, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) highlighted data from its poster presentation at the AACR or American Association of Cancer Research annual Meeting 2019 demonstrating that the targeted radiation delivered by Actimab-A t
Read more →ATNMActinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
NEW YORK, March 29, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the second module of its previously announced research and option agreement with Astellas Pharma Inc. and that the third module has bee
Read more →ATNMActinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
NEW YORK, March 26, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that two oral and four poster presentations related to its Ac-225 or Actinium-225 based ARC's or Antibody Radiation-Conjugates have been accepted for presentation at the
Read more →ATNMActinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
NEW YORK, March 20, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that preclinical data from the novel combination of its CD33 ARC or Antibody Radiation-Conjugate Actimab-A (lintzumab-Ac-225) with venetoclax has been accepted for poste
Read more →ATNMActinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs. In this role, Dr. Gokhale will be responsible for developing and impl
Read more →ATNMActinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) reported its financial results for the fourth quarter and year ended December 31, 2018 as well as provided corporate and operational updates on clinical trials, research and development,
Read more →ATNMActinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that the rejuvenation of R&D activity has bolstered its patent portfolio to a total of 111 issued and pending patents in the U.S. and internationally, which is up from t
Read more →ATNMActinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, being held March 19-20 at the Westin G
Read more →ATNMActinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was...
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was reported in a late breaking oral presentation at the 2019 Transplantation & Cellular Therapy M
Read more →ATNMActinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that it reported data from its Iomab-ACT program in a poster presentation at the 2019 Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR (TCT Meetings). A s
Read more →ATNMIomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations at the 2019 TCT or Transplan
Read more →ATNMActinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced that it has further expanded the intellectual property portfolio for the technology underpinning its Iomab-ACT program. The Iomab-ACT program is being developed for lymphodeplet
Read more →ATNMActinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that its novel Phase 1/2 combination trial of Actimab-A and venetoclax has been initiated. Gary Schiller, MD, Professor, Hematology-Oncology a
Read more →ATNMActinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin
NEW YORK, Feb. 4, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") announced today that the Medical College of Wisconsin (MCW) has started dosing patients in the second cohort of its novel trial of Actimab-A in combination wi
Read more →ATNMActinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th
NEW YORK, Jan. 29, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will host a key opinion leader (KOL) breakfast on targeted conditioning for bone marrow transplant (BMT) and CAR-T from 8:00 AM to 9:
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at Noble Capital Markets
NEW YORK, Jan. 25, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) today announced that it will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 29th at 12:30
Read more →ATNMActinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
NEW YORK, Jan. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today the appointment of Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain. In this position, Ms. Pussinen will s
Read more →ATNMActinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated
NEW YORK, Jan. 17, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the first module of its previously announced research and option agreement with Astellas Pharma Inc. Within the collaboration, the Compa
Read more →ATNMActinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
NEW YORK, Jan. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today the appointment of Qing Liang, PhD as Vice President and Head of Radiation Sciences. This key leadership position will be responsible for exe
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that Sandesh Seth, Actinium's Chairman and Chief Executive Officer will present at the Biotech Showcase™ 2019 being held on January 7-9. The conference will be held at the
Read more →ATNMActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
NEW YORK, Dec. 4, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that additional data from an updated analysis of the pivotal Iomab-B Phase 3 SIERRA trial were highlighted last night in an oral presentation at the 60th American Society o
Read more →ATNMActinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company"), announced today that updated data from its Phase 2 trial of Actimab-A was highlighted in a poster presentation at the 60th American Society of Hematology (AS
Read more →ATNMActinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
NEW YORK, Nov. 19, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that management will present at the 30th Annual Piper Jaffray Healthcare conference that is being held at the Lotte New York Palace hotel, November 26-29. The live webcast
Read more →ATNMActinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference
NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it has been selected to present at the BIO-Europe® 24th Annual International Partnering Conference. The presentation is in addition to the Company's planned partnering
Read more →ATNMActinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data
NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that multiple abstracts highlighting its Antibody Radiation Conjugates (ARCs) have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Me
Read more →ATNMActinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax
NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that the next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program, after successful completion of the Actimab-A phase 2 trial in
Read more →ATNMActinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
NEW YORK, Oct. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will host a conference call and webinar today at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 –
Read more →ATNMActinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference
NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that members of the Company's executive team will attend the BIO-Europe® 24th Annual International Partnering Conference in Copenhagen, Denmark on November 5-7, 2018. BIO-
Read more →ATNMActinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 p
Read more →ATNMActinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers
NEW YORK, Oct. 1, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that is has launched its Iomab-ACT program offering its next-generation, chemo-free, targeted lymphodepletion technology to the CAR-T industr
Read more →ATNMActinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T
NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), will introduce its next generation targeted lymphodepletion technology for CAR-T therapy on a conference call and webcast today at 4:15 PM ET. Actinium's n
Read more →ATNMActinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that the Company will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease, to be held September 26-27, 2018 in New York City. Ma
Read more →ATNMActinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space. CAR-T is a type of cellular therapy
Read more →ATNMActinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
NEW YORK, Sept. 6, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced the appointment of Robert N. Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee
Read more →ATNMActinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions
NEW YORK, Sept. 4, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that it will present at 2018 B. Riley FBR Healthcare Conference on Tuesday, September 4th and at the Maxim Rights Offering Conference on Thursday, September 6th, both of w
Read more →ATNMActinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
NEW YORK, Aug. 14, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company"), today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Trial
Read more →ATNMActinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
Actinium Pharmaceuticals has established a Nuclear Medicine Clinical Advisory Board to enhance its clinical development and commercialization efforts for Iomab-B, which is currently in a pivotal Phase 3 trial. The board comprises leading experts in nuclear medicine, expected to provide valuable insights for the company's targeted therapies. Actinium aims to improve outcomes for patients undergoing bone marrow transplants through its innovative Antibody Radio-Conjugates.
Read more →ATNMActinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
Actinium Pharmaceuticals will host a webcast on July 10, 2018, to discuss its Actimab-A MRD clinical trial for AML patients in remission. The trial aims to evaluate the safety and efficacy of Actimab-A, an antibody radio-conjugate targeting CD33. Key executives, including Dr. Joseph Jurcic and Dr. Mark Berger, will lead the discussion.
Read more →ATNMActinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
Actinium Pharmaceuticals has launched a new clinical trial, Actimab-A MRD, targeting minimal residual disease in postremission acute myeloid leukemia (AML) patients. The trial, led by Dr. Joseph Jurcic, will evaluate the safety and efficacy of Actimab-A as a consolidation therapy. The FDA has cleared the IND application for this trial, which aims to improve progression-free and overall survival rates.
Read more →ATNMActinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
Actinium Pharmaceuticals has announced the dosing of its 38th patient, marking 25% enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B. The trial aims to evaluate the efficacy of Iomab-B in elderly patients with relapsed or refractory acute myeloid leukemia. Recent protocol amendments have expanded treatment options in the control arm, and the company is preparing for additional site activations in the U.S. and Europe.
Read more →ATNMActinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Actinium Pharmaceuticals provided updates from the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, highlighting the formation of two advisory boards aimed at enhancing clinical and commercial strategies. The company is actively engaging with trial investigators for Iomab-B and Actimab programs, with Iomab-B currently in a pivotal Phase 3 trial. Actinium's leadership expressed optimism about the company's progress and future objectives.
Read more →ATNMActinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
Actinium Pharmaceuticals has initiated a Phase 1 trial at the Medical College of Wisconsin, treating its first patient with Actimab-A in combination with the CLAG-M regimen for relapsed or refractory acute myeloid leukemia (AML). This trial aims to evaluate safety, tolerability, and efficacy, potentially improving patient outcomes and expanding treatment options. Actimab-A is an antibody radio-conjugate targeting CD33, a marker prevalent in AML cells.
Read more →ATNMActinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium
Actinium Pharmaceuticals will present at the 19th Annual Bio€quity Europe Conference in Ghent, Belgium, from May 14-16, 2018. The company aims to engage in business development and investor meetings during the event. Actinium's presentation is scheduled for May 15, 2018, at 4:20 p.m. CEST, focusing on its targeted therapies and ongoing clinical trials.
Read more →ATNMActinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors
Actinium Pharmaceuticals has appointed Dr. Jeffrey Chell to its Board of Directors. Dr. Chell brings over 25 years of experience in healthcare, particularly in bone marrow transplantation. His leadership at Be The Match and the National Marrow Donor Program has significantly advanced donor registries and transplant facilitation. Actinium aims to leverage his expertise to enhance its targeted therapies.
Read more →ATNMActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
Actinium Pharmaceuticals has strengthened its clinical development team by hiring Dr. Vijay Reddy as Vice President, Clinical Development, along with Dr. Farnoush Safavi and Kathleen McNamara. The team will focus on the company's targeted myeloablation programs, including the Phase 3 SIERRA trial for Iomab-B and the upcoming Phase 2 Actimab-MDS trial. This expansion aims to enhance the company's leadership in myeloablation therapies.
Read more →ATNMActinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
Actinium Pharmaceuticals will showcase its AWE Technology Platform at the upcoming AACR Annual Meeting, highlighting its potential to develop biobetters, particularly an enhanced version of daratumumab for multiple myeloma. The company will present in vivo data demonstrating superior antitumor activity and survival benefits. Actinium's collaboration with Astellas Pharma further emphasizes the platform's capabilities.
Read more →ATNMPharmaceuticals Reiterates Previously Announced
Pharmaceuticals Reiterates Previously Announced Date of March 2, 2018 at 5:00 PM ET and Amendment to Terms of its Rights Offering YORK, NY - February 26, 2018 - Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it has ame
Read more →ATNMFORM OF INSTRUCTIONS AS TO USE OF SUBSCRIPTION RIGHTS CERTIFICATES ACTINIUM PHARMACEUTICALS, INC. Please consult Broadridge Corporate Issuer Solutions, Inc., as to any questions. The following instructions relate to a ri
INSTRUCTIONS AS TO USE OF SUBSCRIPTION ACTINIUM PHARMACEUTICALS, INC. Please consult Broadridge Corporate Issuer Solutions, Inc., as to any questions. The following instructions relate to a rights offering (the "Rights Offering") by Actinium Pharmaceuticals, Inc., a Delaware
Read more →ATNMUpdate and Outlook for 2018
Update and Outlook for 2018 behalf of the team at Actinium, I would like to wish you all an awesome 2018 and also thank our many shareholders for their unstinting support of the Company's proposals for the Annual Shareholder Meeting in December, all of which passed with resound
Read more →ATNMAnnounces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock York, NY - July 28, 2017 - Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for can
Read more →ATNMActinium Pharmaceuticals Appoints Pharmaceutical
Actinium Pharmaceuticals Appoints Pharmaceutical Ajit S. Shetty, Ph.D., to the Company's Board of Directors - Proven leader with 36 years of experience with Johnson & Johnson in numerousexecutive capacities, most recently as Head of Enterprise Supply Chain - Dr. Shetty was in
Read more →ATNMAnnounces Pricing of Public Offering of Common Stock
Announces Pricing of Public Offering of Common Stock YORK, NY - September 29, 2016 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advance
Read more →ATNMWith Impressive Data in Tow, Actinium Pharma An Overlooked Leader in New AML Therapies
By Elliot Schleicher, Senior Staff Writer, Online Media Group, Inc. NEW YORK, NY, Aug. 10, 2016 /PRNewswire/ - Acute myeloid leukemia (AML) goes by many names, acute myelogenous leukemia and acute myeloblastic leukemia for example, and comes in eight different subtypes, making i
Read more →ATNMActinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones - Iomab-B Pivotal Phase 3 Trial Initiation Signals Transformation of Company Profile to Late
Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones NEW YORK, NY - August 4, 2016 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developin
Read more →ATNMand Memorial Sloan Kettering Cancer Center Sign
and Memorial Sloan Kettering Cancer Center Sign Agreement in Respect of Certain Liquidity Matters Remain Committed to Their Existing Collaborations YORK, NY- December 23, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company developi
Read more →ATNMActinium Files Orphan Drug Application for Use of Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients Orphan Drug Designation Could Provide Faster Regulatory Review and Financial Incent
Files Orphan Drug Application for Use of Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients Drug Designation Could Provide Faster Regulatory Review and Financial Incentives YORK, NY - November 23, 2015 Actinium Pharmaceuticals, Inc. (NYSE MK
Read more →ATNMSubmits Iomab-B IND Application to the U.S.
Submits Iomab-B IND Application to the U.S. FDA Gearing Up For Pivotal, Phase 3 Clinical Trial YORK, NY - November 17, 2015 Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immu
Read more →ATNMLetter to Shareholders
Fellow Shareholders, So far in 2015, Actinium has made many strides to advance our drug candidates, Actimab-A and Iomab-B, in their clinical development and towards eventual commercial launch. I want to summarize for you our many accomplishments in 2015 thus far: 2015 Achieve
Read more →ATNMActinium Pharmaceuticals, I n c . Actinium Announces $5 Million Registered Direct Offering of Common Stock
Pharmaceuticals, Inc. Announces $5 Million Registered Direct Offering of Common Stock YORK, NY, June 4, 2015 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics fo
Read more →ATNMActinium Pharmaceuticals, Inc. Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock NEW YORK, NY, February 6, 2015 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT: ATNM), a biopharmaceutical company developing innovative t
Read more →ATNMActinium Pharmaceuticals, I n c . Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Pharmaceuticals, Inc. Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock NEW YORK, NY, February 5, 2014 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innov
Read more →ATNMActinium Pharmaceuticals, I n c . Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 months in Elderly Secondary Acute Myeloid Leukemia Significant Reduction
Pharmaceuticals, Inc. Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 months in Elderly Secondary Acute Myeloid New York, NY - November 6, 2014 -- Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (N
Read more →ATNMActinium Pharmaceuticals, Inc. ACTINIUM PHARMACEUTICALS PROVIDES MID-YEAR UPDATE DIRECTED AT EXISTING AND FUTURE SHAREHOLDERS Material Progress On All Fronts To Date in 2014 - Including: Pipeline Advances, Improved Stock
Actinium Pharmaceuticals, Inc. PHARMACEUTICALS PROVIDES MID-YEAR UPDATE DIRECTED AT EXISTING AND FUTURE SHAREHOLDERS Progress On All Fronts To Date in 2014 - Including: Pipeline Advances, Improved Stock Market Profile, Stronger Balance Sheet, Fortified Executive Team and Stron
Read more →ATNMActinium Pharmaceuticals, Inc. Actinium Prices $12.5 Million Public Offering of Common Shares
Actinium Pharmaceuticals, Inc. Actinium Prices $12.5 Million Public Offering of Common Shares NEW YORK, NY, June 25, 2014 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunothe
Read more →ATNMActinium Pharmaceuticals, Inc. Actinium Announces Proposed Public Offering of Common Shares
Actinium Pharmaceuticals, Inc. Actinium Announces Proposed Public Offering of Common Shares NEW YORK, NY, June 24, 2014 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunothera
Read more →ATNMACTINIUM TO LIST COMMON STOCK ON NYSE MKT Shares of Common Stock Will Begin Trading on NYSE Mkt on
ACTINIUM TO LIST COMMON STOCK ON NYSE MKT Shares of Common Stock Will Begin Trading on NYSE Mkt on March 26, 2014 NEW YORK, NY - March 24, 2014 - Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative tar
Read more →ATNMActinium Pharmaceuticals, I n c . Actinium Closes on Approximately $6.6 Million in Private Placement Company completes its offering of common stock and warrants
Actinium Pharmaceuticals, Inc. Actinium Closes on Approximately $6.6 Million in Private Placement Company completes its offering of common stock and warrants NEW YORK, NY - January 13, 2014 - Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biop
Read more →ATNMWith Bone Marrow Transplants Rising, New Therapy Gives Hope to Those Over 55
NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S. They are the only potential cure for many blood cancers such as acute myeloid leukemia (AML) in older patients. The procedure is technic
Read more →ATNMFour Things to Ask Your Doctor About Bone Marrow Transplants
NEW YORK, Dec. 20, 2013 /PRNewswire/ -- Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any
Read more →ATNMEncouraging Clinical Data From Multicenter Phase 1/2 Trial On Actinium
NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, were presented in a poster session on
Read more →ATNMActinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave
Read more →ATNMActinium Pharmaceuticals, I n c . ACTINIUM PRESENTING AT THE LD MICRO CONFERENCE TODAY AT 12:30 PM PACIFIC Company Looks Forward to Communicating its Exciting Prospects and Meeting with Conference Attendees
Actinium Pharmaceuticals, Inc. ACTINIUM PRESENTING AT THE LD MICRO CONFERENCE TODAY AT 12:30 PM PACIFIC Company Looks Forward to Communicating its Exciting Prospects and Meeting with Conference Attendees NEW YORK, NY - December 5, 2013 - Actinium Pharmaceuticals, Inc. (OTCQB:
Read more →ATNMActinium Pharmaceuticals Presenting At The LD Micro Conference Today At 12:30 pm Pacific
NEW YORK, Dec. 5, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 12:30 pm Pacif
Read more →ATNMActinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will hold its An
Read more →ATNMActinium Pharmaceutical
BURTON, Mich., Dec. 3, 2013 /PRNewswire/-- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) a pharmaceutical company developing drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients announces analyst coverage. Actinium's drugs ar
Read more →ATNMActinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actinium
NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported today that data from an abstrac
Read more →ATNMActinium Pharmaceuticals To Present At The LD Micro Conference
NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J.
Read more →ATNMActinium Pharmaceuticals Announces Plans For Iomab™-B Phase 3 Pivotal Trial Following Meeting With FDA
NEW YORK, Nov. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its
Read more →ATNMActinium Pharmaceuticals, I n c . ACTINIUM ANNOUNCES PLANS FOR IOMAB -B PHASE 3 PIVOTAL TRIAL FOLLOWING MEETING WITH FDA Company Expects Single Trial Required for Regulatory Approval
Actinium Pharmaceuticals, Inc. ACTINIUM ANNOUNCES PLANS FOR IOMAB -B PHASE 3 PIVOTAL TRIAL FOLLOWING MEETING WITH FDA Company Expects Single Trial Required for Regulatory Approval NEW YORK, NY - November 15, 2013 - Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or
Read more →ATNMActinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. ACTINIUM PHARMACEUTICALS APPOINTS RICHARD STEINHART AS NEW INDEPENDENT DIRECTOR NEW YORK, NY - November 12, 2013 - Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative ta
Read more →ATNMActinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of R
Read more →ATNMActinium Pharmaceuticals To Host Corporate Update And Virtual Roadshow Conference Call On November 11
NEW YORK, Nov. 8, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update
Read more →ATNMActinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
NEW YORK, Oct. 31, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update
Read more →ATNMActinium Pharmaceuticals Webinar To Discuss Iomab™-B At 11AM EDT Today
NEW YORK, Oct. 15, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is hosting an online webinar today a
Read more →ATNMActinium Pharmaceuticals Announces Upcoming Webinar To Discuss Iomab™-B
NEW YORK, Oct. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will be hosting
Read more →ATNMActinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of
Read more →ATNMActinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of
Read more →ATNMActinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants Actinium Pharmaceuticals receives US $3,457,087 in proceeds from the exercise of 2,095,204 A-warrants New York, NY, June 7 , 2013 -- Actinium Pharma
Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants Actinium Pharmaceuticals receives US $3,457,087 in proceeds from the exercise of 2,095,204 A-warrants New York, NY, June 7, 2013 -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent is
Read more →ATNMActinium Pharmaceuticals
NEW YORK, June 5, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced the timing for a presentation devoted to its Acute Myeloid Le
Read more →ATNMActinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT)
Read more →ATNMActinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed
Read more →ATNMCactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
NEW YORK, April 17, 2013 /PRNewswire/ -- Cactus Ventures, Inc. (OTCBB: CTVN; OTCBB: ATNM), (the "Company") announced today that following the change of the Company's name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc., the Company will change the trading symbol of i
Read more →ATNMActinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative alpha particle immunotherapeutics, is pleased to announce that Mr. Jack Talley, Actinium's President & CEO will be presenting at the 15th Annu
Read more →ATNMActinium Pharmaceuticals, Inc. (A Development Stage Company) Consolidated Financial Statements As of
Actinium Pharmaceuticals, Inc. (A Development Stage Company) Consolidated Financial Statements As of September 30, 2012 and December 31, 2011 and for the Nine Months Ended September 30, 2012 and 2011 and for the period from June 13, 2000 (inception) to September 30, 2012 Ac
Read more →ATNMActinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentatio
Read more →ATNMUniversity of Pennsylvania joins Actinium Pharmaceuticals
NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a public biopharmaceutical company (OTC BB: CTVN) that develops innovative targeted payload immunotherapeutics, announced that the University of Pennsylvania Health System in Philadelphia, PA has joined
Read more →ATNMActinium Pharmaceuticals to Present at the Biotech Showcase™ 2013
NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: CTVN) today announced that Jack Talley, the company's President and Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Monday, January 7, 2013 at 11:45 AM Pacific Ti
Read more →ATNMUnaudited pro forma combined financial information of Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. The unaudited pro forma information below gives effect to the share exchange between Cactus Ventures, Inc. an
Unaudited pro forma combined financial information of Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. The unaudited pro forma information below gives effect to the share exchange between Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. as if it had been consumma
Read more →ATNMActinium Pharmaceuticals, Inc. Goes Public via a Reverse Merger into Cactus Ventures, Inc.
NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ("Actinium") announced today that it went public via a reverse merger into Cactus Ventures, Inc. (OTCBB: CTVN), a fully reporting public company (the "Company") pursuant to a share exchange agreement dated Dece
Read more →ATNMAudited Consolidated Financial Statements Actinium Pharmaceuticals, Inc. (A Development Stage Company) Consolidated Financial Statements As of
Actinium Pharmaceuticals, Inc. (A Development Stage Company) Consolidated Financial Statements As of December 31, 2011 and 2010 and for the years ended December 31, 2011 and 2010 and for the period from June 13, 2000 (inception) to December 31, 2011 REPORT OF INDEPENDENT RE
Read more →ATNMActinium Pharmaceuticals, Inc. successfully completes the first closing of $5.1 million in its ongoing funding raise
NEW YORK, Dec. 26, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for treatment of advanced cancers, is pleased to announce that it has successfully completed a first closing of $5.1 million in its current round of financing
Read more →ATNMLetter of Intent
Letter of Intent
Read more →ATNMActinium Pharmaceuticals and Philogen S.p.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program
NEW YORK and SIENA, Italy, Nov. 29, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A. today announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody
Read more →ATNMActinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy". The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and foll
Read more →ATNMActinium Pharmaceuticals Announces Presentation for Actimab-A, a Novel Targeted Immunotherapy for Acute Myeloid Leukemia at the 8th Annual Hematologic Malignancies 2012 Conference
NEW YORK, Oct. 10, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a privately held biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced the presentation of a scientific poster summarizing the results for a Phase I study of A
Read more →ATNMActinium Pharmaceuticals Announces Johns Hopkins University School of Medicine Joins Multicenter Phase I/II Actimab-A Trial
NEW YORK, Oct. 9, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phas
Read more →ATNMDr. Hagop Kantarjian Joins Actinium Pharmaceuticals Clinical Advisory Board
NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Dr. Hagop Kantarjian, MD has joined the Company's Clinical Advisory Board. Dr. Kantarjian who head
Read more →ATNMActinium Pharmaceuticals Announces New Round of Financing
NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that it has engaged Laidlaw & Company (UK) Ltd. and launched a new round of fundraising that will cul
Read more →ATNMGerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API) announced today that Geraldine Henwood, an experienced biopharmaceutical executive, joined the Company's management team in the consultative capacity of Chief Development Officer, Iomab-B. Ms. Henwood w
Read more →ATNMMD Anderson Cancer Center joins Actinium Pharmaceuticals
NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in
Read more →ATNMActinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Company
NEW YORK, Sept. 7, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinica
Read more →ATNMActinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced today that at a General Meeting of its Stockholders held on September 5, 2012, Actinium's shareholders
Read more →ATNMActinium Pharmaceuticals Strengthens Management Team
NEW YORK, Aug. 23, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the Company strengthened the management team with the hiring of Jack V. Talley as President
Read more →ATNMActinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
NEWARK, N.J. and SIENA, Italy, Aug. 9, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A today announced that they have entered into a collaboration agreement under which the companies will explore feasibility and best uses of adding actinium 225 as a payload
Read more →ATNMActinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actinium
NEWARK, N.J., Aug. 1, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Fred Hutchinson Cancer Research Center has become a clinical site for the Company's ongoing Ph
Read more →ATNMActinium Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A™
NEWARK, N.J., July 19, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the f
Read more →Competitive Position
How ATNM ranks across every disease it competes inCompetitive Position is a premium feature
See how ATNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial